Alterity Therapeutics Reports Change in Substantial Holding

Alterity Therapeutics Limited filed a Form 6-K with the SEC on April 27, 2026, reporting a change in substantial holding. The filing serves as a report for a foreign private issuer and incorporates by reference several existing Registration Statements on Forms S-8 and F-3. The primary update contained within the report is Exhibit 99.1, which details a change in substantial holding for the development-stage enterprise. No clinical trial data, regulatory approvals, or financial results were disclosed in this specific filing. The document was signed by Julian Babarczy, the Chairman of Alterity Therapeutics. As a foreign private issuer based in Melbourne, Australia, the company continues to fulfill its reporting obligations under the Securities Exchange Act of 1934. No further corporate developments or strategic shifts were detailed in the provided text.